Please use this identifier to cite or link to this item: http://10.1.7.192:80/jspui/handle/123456789/12189
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSugandh, Atul-
dc.date.accessioned2024-07-04T06:34:42Z-
dc.date.available2024-07-04T06:34:42Z-
dc.date.issued2024-05-
dc.identifier.urihttp://10.1.7.192:80/jspui/handle/123456789/12189-
dc.description.abstractSchizophrenia, a complex psychiatric disorder characterized by disturbances in thinking, perception, and behaviour, poses significant challenges in treatment adherence. Long-acting injectable (LAI) formulations offer a promising solution, ensuring sustained therapeutic drug levels and improving patient compliance. This project focuses on developing LAI depot microspheres for schizophrenia treatment. Pre-formulation studies of both drug and polymer were conducted, including differential scanning calorimetry (DSC), Fourier-transform infrared spectroscopy (FTIR), and melting point analysis, along with standard curve establishment for drug assay by high-performance liquid chromatography (HPLC). The drug selected for this purpose belongs to the antipsychotic class, specifically targeting symptoms associated with schizophrenia. Microspheres were chosen to provide sustained release, enhancing therapeutic efficacy and patient adherence, while the solvent extraction method was selected for its efficiency in microsphere preparation. Initially, batches CI001-CI018 were prepared, with CI014 exhibiting a lag phase due to the use of PLA (Resomer 202S). Subsequently, a blend polymer of PLA and PLGA (Resomer 202S + Resomer 502H) was formulated to address this issue. Analytical testing of batch CI017 included DSC, FTIR, particle size analysis, scanning electron microscopy (SEM), assay determination, related substance, residual solvent analysis, and in vitro dissolution studies. CI017 emerged as the preferred batch, demonstrating sustained drug release over three months. Stability data confirmed the product's integrity over one, three, and six months. This project underscores the significance of LAI microspheres in treating schizophrenia, offering sustained drug delivery and improving patient compliance.en_US
dc.publisherInstitute of Pharmacy, Nirma University, A'baden_US
dc.relation.ispartofseriesPDR00804;-
dc.subjectDissertation Reporten_US
dc.subjectPharmaceuticsen_US
dc.subject22MPHen_US
dc.subject22MPH102en_US
dc.subjectPDR00804en_US
dc.titleFormulation Development and Optimization of Three Month Long-Acting Depot Microspheres for the Treatment of Schizophreniaen_US
dc.typeDissertationen_US
Appears in Collections:M.Pharm. Research Reports, Department of Pharmaceutical Technology and Biopharmaceutics

Files in This Item:
File Description SizeFormat 
PDR00804_22MPH102.pdfPDR008044.23 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.